We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Yourgene Health Plc | LSE:YGEN | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.515 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMYGEN
RNS Number : 2020J
Yourgene Health PLC
19 August 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Yourgene's COVID-19 testing investment reaps rewards
DHSC contract secured to support COVID-19 surge testing
Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that Yourgene Genomic Services ('YGS') has been awarded a contract for provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing by the Department of Health & Social Care (DHSC).
In April 2021, the Company announced it was successful in securing tenders under Public Health England's National Microbiology Framework for Lots 1-4 and was one of only three companies to successfully be awarded all four Lots. This meant public health authorities across the UK were able to issue call-off contracts to procure goods and testing services from Yourgene.
This contract is the first to come of the National Microbiology Framework Lot wins announced earlier this year, using Yourgene's high throughput automated COVID-19 services testing laboratory in Citylabs 1.0, Manchester. The final contract notice value is the maximum estimated value of the contract. Actual value will depend on services purchased. There is no committed spend.
Lyn Rees, Chief Executive Officer, commented: "We are delighted to have been awarded this first contract from the framework, supporting the Government's testing needs utilising our recently completed high throughput COVID-19 diagnostic testing laboratory."
This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122 Lyn Rees, Chief Executive Officer investors@yourgene-health.com Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880 Liam Murray / James Caithie / Ludovico Lazzaretti Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000 Broker) Aubrey Powell / Tom Salvesen / George Tzimas Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600 Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Relations) Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger(R) Technology, the Yourgene LightBench(R) and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". Follow us on LinkedIn and Twitter .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
CNTPLMBTMTMBBTB
(END) Dow Jones Newswires
August 19, 2021 07:04 ET (11:04 GMT)
1 Year Yourgene Health Chart |
1 Month Yourgene Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions